Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition

Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity. The post Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition appeared first…

Read More

How Unaffordable is Health Care?

In his latest JAMA Forum column, KFF’s Larry Levitt explores how unaffordable health care is in the U.S. in the context of the debate over extending enhanced Affordable Care Act premium tax credits and an upcoming election where affordability will likely be front and center.

Read More

Solving the Home Care Quandary

You’re ready to leave the hospital, but you don’t feel able to care for yourself at home yet. Or, you’ve completed a couple of weeks in rehab. Can you handle your complicated medication regimen, along with shopping and cooking? Perhaps you fell in the shower, and now your family wants you to arrange help with…

Read More

Most Favored Nation Drug Pricing in the U.S.: Comparing GENEROUS, GLOBE and GUARD

The Trump administration has introduced three most-favored-nation (MFN) drug pricing initiatives designed to link U.S. pharmaceutical costs to prices paid in economically comparable countries. Most-favored-nation pricing requires manufacturers to provide rebates when U.S. prices exceed those in reference nations—a direct response to the persistent gap between U.S. drug prices and those in other developed economies….

Read More